Drugs / VAL201
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02280317 | Oct 2014 → Jan 2020 | prostate carcinoma | ValiRx Plc | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 8
| Date | Issuer | Release |
|---|---|---|
| 2020-11-30 | ValiRx Plc | Results ValiRx PLC - VAL201 Clinical Trial Full Data Results valirx.com ↗
The dataset provides a complete breakdown of the full data of safety and tolerability as well as evidence for encouraging disease impact as observed during the clinical trial. |
| 2020-09-28 | ValiRx Plc | Results ValiRx PLC - VAL201 Clinical Trial Update valirx.com ↗ |
| 2019-12-16 | ValiRx Plc | Results ValiRx PLC - VAL201 Update valirx.com ↗
The results appear, in advance of full analysis, to indicate that the VAL201 compound has a clear impact on patients with prostate cancer, as measured by PSA - evidence that is supported from tumour imaging (MRI and CT) in subjects. |
| 2019-11-28 | ValiRx Plc | Regulatory ValiRx PLC - US Patent Grant re VAL201 & Metastatic Cancer valirx.com ↗
ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, announces that the US Patent and Trademark Office has granted the US Patent No. 10,400,008 and title: "Modulators Of The SRC-Kinase Activity For Preventing Or Treating Metastatic Cancer", to the Company's lead therapeutic compound, VAL201. |
| 2019-09-10 | ValiRx Plc | Results ValiRx PLC - VAL201 Update valirx.com ↗
ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, today announces that its lead therapeutic compound, VAL201, has thus far and continues to meet all the published endpoints in its first-in-human study. |
| 2019-06-26 | ValiRx Plc | Regulatory ValiRx PLC - US Notice of Allowance-VAL201 & Metastatic Cancer valirx.com ↗ |
| 2019-06-20 | ValiRx Plc | Regulatory ValiRx PLC - Update on VAL201 Clinical Trial valirx.com ↗
ValiRx is pleased to announce that based on its clinical results, a substantial amendment to the clinical trial protocol has received regulatory approval from the Medicines and Healthcare products Regulatory Agency ("MHRA") and the Research ethics committee (REC) |
| 2019-03-21 | ValiRx Plc | Results ValiRx PLC - Update on VAL201 & VAL301 Development Progress valirx.com ↗
ValiRx have established that VAL201 is safe and well tolerated at doses of up to 4mg/kg and the Company can report that it has seen primary evidence of the drug's activity in prostate cancer. |
All press releases naming this drug 15 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VAL201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02280317 ↗ |
| Route | Subcutaneous | “Sub-cutaneous injection” NCT02280317 ↗ |